AI-powered bioinformatics company PathAI has launched PathExplore, which the company claims is the world’s first AI-powered pathology tool that provides standardized and scalable panel of human interpretable features (HIFs) for analyzing the tumor microenvironment (TME) with deep resolution. It provides oncology drug developers with high resolution of the TME, enabling researchers to unlock insights that will inform the next phase of targeted oncology drug development.
PathExplore generates a panel of over 600 quantitative HIFs to analyze the TME with single-cell resolution, producing overlay visualizations of cell types and tissue regions that are accessible on PathAI's AISight Translational Research platform. The AI-powered tool has been trained using more than 6.5 million annotations by pathologists on 66,000 slides. Currently, PathExplore is available for eight cancers, including breast cancer, colorectal cancer, non-small cell lung cancer and pancreatic cancer, with more planned to launch later this year.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.